EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study

Paarth B Dodhiawala iD, Kyle Pribyl, Jared Larson, Victor Vakayil, Malavika Chandrashekar, Amanda Lord, Julie Welbig, Nicole D Zantek, David Martin, James V Harmon

Clinical and Applied Thrombosis/Hemostasis · 2023

DOI: 10.1177/10760296231198038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Paarth B Dodhiawala und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Scientist Training Program, University of Minnesota, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Blood Coagulation Disorders, Liver Diseases. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The administration of 4-factor prothrombin complex concentrate (4F-PCC) has expanded beyond its Food and Drug Administration (FDA)-approved indication for the emergent reversal of vitamin K antagonists (VKAs). Therefore, this study aimed to evaluate the risks and benefits associated with the expanded use of 4F-PCC. We conducted a single-center retrospective review of 4F-PCC administrations at our university hospital. Of the 159 patients who received 4F-PCC, 76% (n = 121) and 24% (n = 38) received it for the FDA-approved indication in the vitamin K-related coagulopathy (VKA) group and for expanded use in the nonvitamin K-related coagulopathy (nVKA) group, respectively. The expanded use of 4F-PCC was associated with a less robust reduction in the international normalized ratio (INR) (INR of −0.7 ± 1.3 vs INR of −1.6 ± 1.8, P = .002), and fewer patients in the nVKA group achieved a postadministration INR of less than1.5 (11% vs 79%, P = .001) than those in the VKA group. Furthermore, the 30-day mortality rate was significantly higher in the nVKA cohort than in the VKA cohort (42% vs 20%, P = .04). Notably, based on our data, underlying differences in the patient’s comorbidities, particularly advanced liver disease, may have contributed to the observed outcome variations, including mortality rate. Therefore, factors, including comorbidities and the underlying etiology of coagulopathy, should be considered when deciding on the expanded use of 4F-PCC. Further research is needed to better understand the potential risks and benefits of 4F-PCC in expanded use scenarios, and the clinical decision to use 4F-PCC outside its FDA-approved indication should be made carefully, considering this information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Coagulation DisordersLiver DiseasesHumansRetrospective StudiesBlood Coagulation FactorsFactor IXVitamin KAnticoagulantsInternational Normalized Ratio

Stichwörter der Autor:innen

4-factor prothrombin complex concentrate4F-PCCcoagulopathyliver diseasenonvitamin K antagonist

Substanzen

prothrombin complex concentratesBlood Coagulation FactorsFactor IXVitamin KAnticoagulants

Autor:innen und Institutionen

  • Medical Scientist Training Program, University of Minnesota, Minneapolis, MN, USA.
  • University of Minnesota Medical School, Minneapolis, MN, USA.
  • Department of Anesthesia, University of Minnesota, Minneapolis, MN, USA.
  • Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA.
  • Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
  • Laboratory Administration, Fairview Health Services, St. Paul, MN, USA.

ORCID-Profile: Paarth B Dodhiawala

Zitieren

APA

Dodhiawala, P. B., Pribyl, K., Larson, J., Vakayil, V., Chandrashekar, M., Lord, A., Welbig, J., Zantek, N. D., Martin, D., & Harmon, J. V. (2023). Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296231198038

Vancouver

Dodhiawala PB, Pribyl K, Larson J, Vakayil V, Chandrashekar M, Lord A, et al. Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296231198038

BibTeX
@article{Dodhiawala2023,
  author = {Dodhiawala, Paarth B and Pribyl, Kyle and Larson, Jared and Vakayil, Victor and Chandrashekar, Malavika and Lord, Amanda and Welbig, Julie and Zantek, Nicole D and Martin, David and Harmon, James V},
  title = {Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2023},
  doi = {10.1177/10760296231198038}
}
Kostenlos starten →